These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32816723)

  • 1. Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing.
    Muilwijk EW; de Lange DW; Schouten JA; Wasmann RE; Ter Heine R; Burger DM; Colbers A; Haas PJ; Verweij PE; Pickkers P; Brüggemann RJ
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32816723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.
    Boonstra JM; Märtson AG; Sandaradura I; Kosterink JGW; van der Werf TS; Marriott DJE; Zijlstra JG; Touw DJ; Alffenaar JWC
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Sinnollareddy MG; Roger C; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6550-6557. PubMed ID: 27550344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.
    Patel K; Roberts JA; Lipman J; Tett SE; Deldot ME; Kirkpatrick CM
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5868-73. PubMed ID: 21930888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy.
    Wang C; Chen J; Yang B; Li S; Zhang Y; Chen L; Wang T; Dong Y
    Pharmacotherapy; 2023 Mar; 43(3):180-188. PubMed ID: 36714991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy.
    Sandaradura I; Marriott DJE; Day RO; Norris RLG; Pang E; Stocker SL; Reuter SE
    Eur J Clin Microbiol Infect Dis; 2021 Jul; 40(7):1521-1528. PubMed ID: 33638727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
    Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M
    Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem.
    Li Z; Bai J; Wen A; Shen S; Duan M; Li X
    Clin Ther; 2020 Aug; 42(8):1564-1577.e8. PubMed ID: 32741646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.
    Gharibian KN; Mueller BA
    Clin Nephrol; 2016 Jul; 86(7):43-50. PubMed ID: 27251341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
    Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
    Leuppi-Taegtmeyer AB; Decosterd L; Osthoff M; Mueller NJ; Buclin T; Corti N
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of daptomycin in critically ill patients.
    Soraluce A; Asín-Prieto E; Rodríguez-Gascón A; Barrasa H; Maynar J; Carcelero E; Soy D; Isla A
    Int J Antimicrob Agents; 2018 Aug; 52(2):158-165. PubMed ID: 29572042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.